Dawson NA - Search Results

1

Berger TG, Dawson NA. Berger TG, et al. Among authors: dawson na. J Am Acad Dermatol. 1988 Feb;18(2 Pt 2):407-12. doi: 10.1016/s0190-9622(88)70058-4. J Am Acad Dermatol. 1988. PMID: 3278019 Review.

2

Neoplastic angioendotheliomatosis. A variant of malignant lymphoma immunohistochemical and ultrastructural observations of three cases.

Elner VM, Hidayat AA, Charles NC, Davitz MA, Smith ME, Burgess D, Dawson N. Elner VM, et al. Ophthalmology. 1986 Sep;93(9):1237-45. Ophthalmology. 1986. PMID: 3808635

3

Suramin-induced skin reactions.

O'Donnell BP, Dawson NA, Weiss RB, Myers CE, James WD. O'Donnell BP, et al. Among authors: dawson na. Arch Dermatol. 1992 Jan;128(1):75-9. Arch Dermatol. 1992. PMID: 1531404

4

Cancer and Leukemia Group B trials for advanced prostate cancer.

Small EJ, Dawson NA, Kantoff PW, Vogelzang NJ. Small EJ, et al. Among authors: dawson na. Semin Oncol. 1996 Dec;23(6 Suppl 14):28-31. Semin Oncol. 1996. PMID: 8996582 Review.

5

Chemotherapy of disseminated Merkel-cell carcinoma.

Redmond J 3rd, Perry J, Sowray P, Vukelja SJ, Dawson N. Redmond J 3rd, et al. Am J Clin Oncol. 1991 Aug;14(4):305-7. doi: 10.1097/00000421-199108000-00006. Am J Clin Oncol. 1991. PMID: 1862761

6

A pilot trial of chemohormonal therapy for metastatic prostate carcinoma.

Dawson NA, Wilding G, Weiss RB, McLeod DG, Linehan WM, Frank JA, Jacob JL, Gelmann EP. Dawson NA, et al. Cancer. 1992 Jan 1;69(1):213-8. doi: 10.1002/1097-0142(19920101)69:1<213::aid-cncr2820690135>3.0.co;2-v. Cancer. 1992. PMID: 1727665 Clinical Trial.

7

A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.

Bowden CJ, Figg WD, Dawson NA, Sartor O, Bitton RJ, Weinberger MS, Headlee D, Reed E, Myers CE, Cooper MR. Bowden CJ, et al. Among authors: dawson na. Cancer Chemother Pharmacol. 1996;39(1-2):1-8. doi: 10.1007/s002800050531. Cancer Chemother Pharmacol. 1996. PMID: 8995493 Clinical Trial.

8

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.

Dawson NA, Figg WD, Cooper MR, Sartor O, Bergan RC, Senderowicz AM, Steinberg SM, Tompkins A, Weinberger B, Sausville EA, Reed E, Myers CE. Dawson NA, et al. J Clin Oncol. 1997 Apr;15(4):1470-7. doi: 10.1200/JCO.1997.15.4.1470. J Clin Oncol. 1997. PMID: 9193342 Clinical Trial.

9

Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables.

Dawson NA, Cooper MR, Figg WD, Headlee DJ, Thibault A, Bergan RC, Steinberg SM, Sausville EA, Myers CE, Sartor O. Dawson NA, et al. Cancer. 1995 Aug 1;76(3):453-62. doi: 10.1002/1097-0142(19950801)76:3<453::aid-cncr2820760316>3.0.co;2-e. Cancer. 1995. PMID: 8625127 Clinical Trial.

10

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer.

Myers C, Cooper M, Stein C, LaRocca R, Walther MM, Weiss G, Choyke P, Dawson N, Steinberg S, Uhrich MM, et al. Myers C, et al. J Clin Oncol. 1992 Jun;10(6):881-9. doi: 10.1200/JCO.1992.10.6.881. J Clin Oncol. 1992. PMID: 1375283 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

122 results

Search Page